Suchen Sie nach Informationen zu Ipsen-Zentrale? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
In 2021, we achieved incredible growth and change as we implemented our strategy; ‘Focus. Together. For Patients & Society.’. From growing our pipeline with external innovation to researching and developing new treatments, we’re proud of our progress and excited to go further in 2022. Discover our 2021 Annual Report.
https://www.ipsen.com/us/
Inspiring hope, improving patients' lives. We are a global biopharmaceutical leader dedicated to improving lives through innovative medicines in oncology, neuroscience, and rare disease. Get to know us Careers.
https://www.ipsen.com/us/about/
Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care. Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare ...
https://www.ipsenusa.com/contact-us/
For general information and inquiries, please use the form below to get connected with an Ipsen team member. Name (Required) First Last. Email (Required) Phone (Required) Title (Required) Company. Address.
https://www.ipsen.com/uk-ireland/
About us. Ipsen was first established as a business in the UK in 1981, and in Ireland in 1989. Today, the UK & Ireland forms a critical and growing part of our Global network and is one of our core operating hubs alongside Cambridge, M.A., USA and Paris, France. As a UK & Ireland Hub we are collaborating to deliver outcomes for patients, health ...
https://www.ipsen.com/press-releases/ipsen-presents-strong-full-year-2021-results-and-enters-into-exclusive-negotiations-to-divest-its-consumer-healthcare-business/
Strong 2021 financial performance with total-sales growth of 12.3% at CER 1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%); Exclusive negotiations with Mayoly Spindler to divest Ipsen’s Consumer Healthcare (CHC) business with a total enterprise value up to €350m and an anticipated closing of the …
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Ipsen-Zentrale gefunden haben.
